# Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors

> **NCT06501183** · PHASE1 · RECRUITING · sponsor: **Shanghai Pudong Hospital** · enrollment: 17 (estimated)

## Conditions studied

- CDH17-positive Advanced Malignant Solid Tumors

## Interventions

- **BIOLOGICAL:** Anti-CDH17 CAR-T cells

## Key facts

- **NCT ID:** NCT06501183
- **Lead sponsor:** Shanghai Pudong Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-08
- **Primary completion:** 2025-05-30
- **Final completion:** 2026-05-30
- **Target enrollment:** 17 (ESTIMATED)
- **Last updated:** 2024-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06501183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06501183, "Anti-CDH17 CAR-T Cell Injection in Patients With CDH17-positive Advanced Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06501183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*